Saladax Biomedical Enters into Master Collaboration Agreement with Bristol-Myers Squibb

Partnership to Advance Multiple Feasibility Studies and Companion Diagnostic Projects

Bethlehem, PA, August 6, 2012 – Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today the company has expanded its existing relationship with Bristol-Myers Squibb Company (NYSE: BMY) by entering into a Master Early Development Collaboration Agreement, which may include multiple feasibility studies and companion diagnostic development projects. With the signing of this agreement, the companies have already initiated a new companion diagnostic project in an undisclosed field. Terms of the agreement were not disclosed.

“Saladax is delighted to continue working with Bristol-Myers Squibb to deliver on the promise of personalized medicine,” said Kevin M. Harter, president and CEO of Saladax. “Building on our previous work together, which resulted in clinically valuable Alzheimer’s disease assays, we’re eager to continue marrying the scientific and clinical knowledge of Bristol-Myers Squibb and Saladax to improve the lives of patients in other clinical areas.”

Saladax and Bristol-Myers Squibb originally entered into a collaboration in 2010 for the development of clinical diagnostic tests for Alzheimer’s disease to be used in conjunction with the development of certain therapeutic compounds in the Bristol-Myers Squibb pipeline. In 2011, that partnership was expanded to include a commercial partner, Johnson & Johnson’s Ortho Clinical Division.

About Saladax Biomedical, Inc.   Saladax Biomedical develops novel diagnostic assays for the practical delivery of personalized medicine. Our proprietary line of MyCareTM assays improves the efficacy of existing drugs by optimizing the dose administered for each individual patient. Saladaxʼs initial focus is oncology, with a portfolio of 13 chemotherapy drug assays in various stages of development. Three MyCare assays, My5- FUTM, MyPaclitaxelTM and MyDocetaxelTM, are currently offered to the oncology community in some markets.

The companyʼs MyCare technology platform is broad and flexible, enabling wide application in many therapeutic categories. This technology capability also enables Saladax to serve as a valuable partner to pharmaceutical and biotechnology companies in the development of companion diagnostics (CDx), addressing multiple risks and challenges encountered in drug development.

The company was founded in 2004 and is headquartered in Bethlehem, Pennsylvania. Saladax is ISO 13485:2003 certified.

Saladax Biomedical, Inc.
Kevin M. Harter, 
President and Chief Executive Officer  
Media Contact:  
Tiberend Strategic Advisors, Inc.   212-827-0020 
Andrew Mielach: moc.d1493618931nereb1493618931it@hc1493618931aleim1493618931a1493618931
or Claire Sojda:   moc.d1493618931nereb1493618931it@ad1493618931josc 1493618931


  • The Funding Process

    The Funding Process

    The Life Sciences Greenhouse of Central Pennsylvania provides investment funding up to $1 million in milestone-driven convertible…

    Read more
  • Our Resource Center


    It’s a familiar scenario. You hear about a discovery that could lead to the cure for this disease or that debilitating…

    Read more
  • The 'PA' in LSGPA


    The Life Sciences Greenhouse of Central Pennsylvania’s 42-county service area contains more than 60 institutions of higher …

    Read more